Press Releases

Novan Achieves Target Enrollment for Phase 2 Acne Study

March 18, 2015

DURHAM, N.C. - Novan Therapeutics, a clinical-stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, today announced that the Company has achieved target enrollment in its Phase 2b clinical study with SB204 for the treatment of acne vulgaris.  Acne is the most common skin disease in the United States, affecting more than 50 million people. 

Full Story

Novan Expands Leadership Team with Vice President of Regulatory Affairs

February 26, 2015

DURHAM, N.C. - Novan Therapeutics, a clinical stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, today announced that Kevin Barber, Ph.D., has been appointed to the newly created position of Vice President of Regulatory Affairs, effective immediately.  Dr. Barber will direct Novan’s regulatory strategy as the primary interface with the FDA and will report directly to Dr. Nathan Stasko, Novan’s President. 

Full Story

Novan to Present Successful Clinical Study Results of Lead Product Candidate SB204 for the Treatment of Acne Vulgaris

January 15, 2015

DURHAM, N.C. - Novan Therapeutics, a clinical stage biotech company focused on advancing nitric oxide therapies, announced today that data from a clinical study to assess the safety and pharmacokinetics of SB204 Gel in patients with moderate to severe acne was accepted for presentation at the World Congress of Dermatology to be held in Vancouver on June 8-15, 2015.  

Full Story

Novan’s Nitric Oxide Drug Candidate Inhibits Growth of Papillomavirus in Translational Animal Model

September 8, 2014

DURHAM, N.C. - Novan Therapeutics, a clinical-stage biotech company focused on advancing nitric oxide therapies, announced today that Novan’s nitric oxide drug candidate SB206 was shown to inhibit papilloma growth in a preclinical animal study. 

Full Story

Close
Close